Nanoscope's MCO-010 Secures Japan's Sakigake and Orphan Drug Designations for Retinal Therapies
Event summary
- Japan's MHLW granted Sakigake and Orphan Drug designations to Nanoscope's MCO-010 for inherited retinal diseases, a first for a retinal gene therapy.
- MCO-010 is the first retinal gene therapy to receive both Sakigake and Orphan Drug designations in Japan.
- The designations enable an accelerated regulatory pathway, including a six-month review timeline and potential premium pricing post-approval.
- MCO-010 has also received multiple expedited programs from the FDA and EMA, positioning it for global pre-commercialization readiness.
- The FDA, EMA, and PMDA conditionally approved the brand name MOGENRY™ for MCO-010.
The big picture
Nanoscope's MCO-010 is now positioned as the most advanced optogenetic platform therapy in development, with accelerated regulatory pathways established in Japan, the U.S., and Europe. This strategic milestone underscores the company's leadership in optogenetic therapy and its potential to address profound vision loss where no approved treatments exist. The coordinated designations support accelerated development timelines and enhanced regulatory engagement, positioning MCO-010 for potential first-mover advantage in the optogenetic therapy space.
What we're watching
- Regulatory Momentum
- Whether Nanoscope can sustain this global regulatory momentum to accelerate MCO-010's approval timelines across major markets.
- Commercialization Strategy
- The pace at which Nanoscope advances its rolling BLA submission for retinitis pigmentosa in the U.S. and initiates Phase 3 trials for Stargardt disease.
- Market Positioning
- How Nanoscope leverages the Sakigake and Orphan Drug designations to position MCO-010 as a potential standard of care for inherited retinal diseases.
Related topics